P1vital PReDicT Test - ECO14: Patient Safety

www.p1vitalproducts.com 1

www.p1vitalproducts.com

What’s the problem?

Depression is the number one cause of disability in the world (WHO – 2017)

Mental health and behavioural conditions Account for 31% of all fit notes(NHS digital 2017)

Cost to government inc NHS £24 - £27 billion

Cost to employers (absenteeism /

presenteeism)

£33 - £42 billion

# antidepressants dispensed in 2016 64.7 million (doubling over last decade)

# people per year to receive antidepressant

therapy for 1st time and/or recurring episode

800,000

# patients who will not respond to 1st

treatment they are given

~50%; each treatment cycle takes 4-6

weeks to detect response

Reoccurrence of depression 50% after 1st; 70% after 2nd; 90% after 3rd

2


What’s the solution?

Holistic approach to the management of depression is required

Better understanding of the disease, its treatment and prevention

Awareness of the triggers and risk factors for depression

Social withdrawal as an early indicator on coming depressive episode

Preventing re-occurrence

Reducing suicide

Leverage our understanding of how treatments for depression work

Negative emotional bias as a precursor of oncoming mood

3


HAPPY

ANGRY CONTEMPT DISGUST SADNESS

FEAR SURPRISE

The PReDicT Test works by measuring subtle changes in the way patients

interpret emotional information through their recognition of facial expressions


P1vital® PReDicT Test

Improves treatment of depression

Quickly detects if treatment is not

working

Monitors patient symptoms

Assesses symptom severity

Multi-platform, easy to use

marked medical device

Improves clinical decision making

Reduces GP practice visits

Accelerates patient recovery via

medicines optimisation

Reduces side effects associated

with inappropriate prescribing

Reduce healthcare costs

5

FEATURES BENEFITS



EU Horizon 2020 SME award

Phase 2 award - €4M for PReDicT

http://predictproject.p1vitalproducts.com/

PReDicT study ongoing across 5 EU

countries including UK, with results

due out early 2019

PReDicT Test so far deployed in:

24 GP surgeries in England;

completed by 323 depressed

patients

32 clinical practices across

mainland Europe; completed by

173 depressed patients

Preliminary UK data (N=217)

shows:

After 8w, more people responding

to antidepressant treatment:

PReDicT 67% vs TaU 51%

GPs willing to change medications

on reviewing PReDicT data

Patient engagement is high

6

Patients prescribed

antidepressant

No response

Switch antidepressant

No response

Increase dose

Week 0

Week 4-6

Week 8-12

Week 0

PReDicT

Week 1

PReDicT

Week 2

PReDicT

TaU PReDicT

Reduce 8–12 week cycle to a 2 week cycle

http://predictproject.p1vitalproducts.com/


Working together to provide a holistic solution

for patients living with depression

With NHS, wish to optimise real world implementation of the PReDicT Test

to enable its wider deployment across UK primary care to determine real

healthcare benefits

Looking for early adopters:

CCG engagement to demonstrate the business case for adoption

GP partnerships for participation in implementation studies

Ideal: PPL collaboration with NHS, DWP/W&H programme & Employer to

demonstrate value proposition of the PReDicT Test to better manage

depression

7

Poor

health/well

being

Good

health/

well being

Family

History of

depression

PReDicT

Digital

assessments

PReDicT

Antidepressants

IAPT

PReDicT

Monitoring and

alerts

PReDicT

TRD

PReDicT Suicide

Alerts

Healthy At RiskAcute

InterventionContinuation and risk of relapse Suicide risk

Employer and W&H NHS and W&H

Health & Medicine

P1vital PReDicT Test - ECO14: Patient Safety